Compass Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period
Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics for solid tumors and hematological malignancies, including CTX-471, CTX-8371, CTX-8573 and an NKp30 innate-cell-engager platform. The filing covers the three and six months ended June 30, 2020 and was filed August 13, 2020.
On June 17, 2020, the company completed a reverse merger with Compass Therapeutics LLC, which became its wholly owned subsidiary. The transaction was accounted for as a recapitalization and reverse acquisition, with Compass Therapeutics LLC treated as the accounting acquirer. On June 19, 2020, the company sold 12,096,442 common shares at $5.00 per share in a private placement.
Financial position and key metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $3.0 million vs. $5.4 million | $6.6 million vs. $12.6 million |
| General and administrative expense | $2.1 million vs. $3.3 million | $4.3 million vs. $6.6 million |
| Total operating expenses | $5.1 million vs. $8.7 million | $10.9 million vs. $19.3 million |
| Net loss | $5.6 million vs. $8.8 million | $12.0 million vs. $19.6 million |
| Basic and diluted loss per share | $0.41 loss vs. $1.33 loss | $1.16 loss vs. $3.00 loss |
| Cash used in operating activities | Not separately provided | $13.1 million vs. $19.4 million |
| Cash provided by financing activities | Not separately provided | $53.1 million vs. none |
At June 30, 2020, cash and cash equivalents were $65.4 million, restricted cash was $0.3 million and total assets were $70.4 million. Accumulated deficit was $133.9 million. The filing does not provide a meaningful revenue-based operating or gross margin because the company has no product sales.
Total debt was $13.1 million net of debt discount, consisting of $7.5 million current debt and $5.6 million long-term debt. The facility bears interest at the greater of 6.25% or prime plus an applicable margin; the stated interest rate was 6.75% at June 30, 2020. Monthly principal payments of $625,000 began in April 2020, and the facility matures in March 2022. The company was in compliance with its debt covenants and was required to maintain a minimum cash balance of $6.0 million.
Material changes versus the prior comparable period
- Six-month operating expenses declined $8.4 million, primarily because of reduced research and development headcount, completion of CTX-471 preclinical work, and lower external and legal expenses.
- Research and development expense declined $6.1 million, partly offset by initial CTX-471 clinical-trial costs and early CTX-8371 activities.
- General and administrative expense declined $2.3 million due primarily to lower headcount, legal fees and consulting expenses.
- Net loss improved by $7.6 million for the six-month period, although the company continued to incur substantial losses.
- Cash increased by $40.1 million during the first six months, primarily from the private placement, partly offset by $13.1 million of operating cash use and $1.9 million of debt repayments.
- The reverse merger converted all outstanding preferred membership interests into common stock. Common shares outstanding at June 30, 2020 were 50.9 million; 52.2 million shares were outstanding as of August 1, 2020.
- The company settled the $1.1 million loan success fee associated with the merger. The related derivative liability was zero at June 30, 2020, compared with $0.5 million at December 31, 2019.
Guidance, outlook, commentary and risks
Management expects cash and cash equivalents to fund operating expenses and capital expenditures into the fourth quarter of 2021, based on current plans and assumptions. Management expects to use available resources to continue the CTX-471 Phase 1 program, advance CTX-8371 toward Phase 1 development after IND-enabling work, and advance CTX-8573 and the NKp30 program through IND-enabling activities. The company states that additional funding will be required thereafter and potentially sooner if assumptions change.
The company expects research and development and general and administrative expenses to increase as clinical development advances and as it incurs costs associated with operating as a public company. It has never generated product revenue and does not expect product revenue in the near future, if at all.
COVID-19 had not caused major delays in the ongoing CTX-471 Phase 1 trial as of the filing, but management identified potential risks to patient enrollment, trial-site access, manufacturing, supply chains, staffing and future trial timelines.
As of May 24, 2020, 19 patients had received at least one dose of CTX-471. The filing reports six serious adverse events, including two considered treatment-related, and two dose-limiting toxicities involving immune-related thrombocytopenia. The reported treatment-related events had resolved.
In July 2020, the company entered into a manufacturing agreement for CTX-8371. The contract manufacturing organization may receive up to $4.85 million as specified manufacturing and protocol milestones are completed.
Principal risks include continued operating losses, the need for substantial additional capital, clinical and regulatory failure, adverse events, manufacturing dependence, intellectual-property uncertainty, competition, reliance on third parties, COVID-19 disruptions and the absence of a trading market for the common stock. The company reported no material legal proceedings and no off-balance-sheet arrangements.
Management concluded that disclosure controls and procedures were effective as of June 30, 2020. Neither the company nor its independent registered public accounting firm had performed an internal-control effectiveness evaluation for the periods covered by the report.
Important facts for investors to verify
- Confirm the post-merger capitalization, including the 52.2 million shares outstanding as of August 1, 2020, restricted shares, warrants and the 2020 equity incentive plan.
- Assess whether the $65.4 million cash balance and projected runway to the fourth quarter of 2021 remain reasonable after planned clinical, manufacturing and public-company expenditures.
- Review CTX-471 clinical-trial enrollment, safety data, dose-limiting toxicities and any subsequent regulatory or clinical updates.
- Monitor the CTX-8371 manufacturing agreement and potential milestone payments of up to $4.85 million.
- Review debt amortization, the $6.0 million minimum cash covenant, interest-rate exposure and maturity obligations through March 2022.
- Verify the status of resale registration for shares issued in the reverse merger and private placement and the implications of the company’s former shell-company status.
- Evaluate future financing needs and the potential dilution, restrictive covenants or loss of rights associated with equity, debt or collaboration financing.